

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasvgl614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks
(ROSPATENT) added to list of core patent offices covered
NEWS 4 FEB 28 PATDPAFULL - New display fields provide for legal status
data from INPADO
NEWS 5 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 6 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 7 MAR 02 GBFULL: New full-text patent database on STN
NEWS 8 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 9 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 10 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 11 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 12 MAR 22 PATDPASPC - New patent database available
NEWS 13 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 14 APR 04 EPFULL enhanced with additional patent information and new
fields
NEWS 15 APR 04 EMBASE - Database reloaded and enhanced
NEWS 16 APR 18 New CAS Information Use Policies available online

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:29:43 ON 18 APR 2005

=> File reg

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE
ENTRY

0.84

TOTAL
SESSION

0.84

FILE 'REGISTRY' ENTERED AT 11:31:50 ON 18 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 APR 2005 HIGHEST RN 848640-07-3
DICTIONARY FILE UPDATES: 17 APR 2005 HIGHEST RN 848640-07-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Documents and Settings\sgembeh\My Documents\p-gb.str

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s L1 exa full

FULL SEARCH INITIATED 11:33:39 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L2 0 SEA EXA FUL L1

=> File Caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

65.86

66.70

FILE 'CAPLUS' ENTERED AT 11:48:05 ON 18 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Apr 2005 VOL 142 ISS 17
FILE LAST UPDATED: 17 Apr 2005 (20050417/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s us2004-7919122/ap
L3 0 US2004-7919122/AP

=> s US2004-791922/ap
L4 1 US2004-791922/AP

=> d all

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:912855 CAPLUS
DN 139:374999
ED Entered STN: 21 Nov 2003
TI Methods using P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells
IN Johnson, William W.; Wang, Er-Jia; Casciano, Christopher; Clement, Roger P.
PA Schering Corporation, USA
SO U.S. Pat. Appl. Publ., 70 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-473
NCL 514290000
CC 1-6 (Pharmacology)
Section cross-reference(s): 28
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003216422	A1	20031120	US 2002-104554	20020322
	US 6703400	B2	20040309		
	US 2004176403	A1	20040909	US 2004-791922	20040303 <--
PRAI	US 2002-104554	A1	20020322		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 2003216422	ICM	A61K031-473	
	NCL	514290000	
US 2003216422	ECLA	A61K031/473+M; A61K045/06	
US 2004176403	ECLA	A61K031/473+M; A61K045/06	<--
OS	MARPAT	139:374999	
AB		Methods are provided for treating multidrug resistance in refractory tumor	

cells comprising administering a P-glycoprotein inhibitor in conjunction with an antineoplastic agent. P-glycoprotein inhibitors include SCH 66336 and other tricyclic derivs. (preparation of selected compds. is described).

ST antitumor multidrug resistance treatment P glycoprotein inhibitor; tricyclic deriv prepn P glycoprotein inhibitor antitumor multidrug resistance; SCH 66336 P glycoprotein inhibitor antitumor multidrug resistance treatment

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDR1; P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT Antitumor agents
 Biological transport
 Human
 Multidrug resistance
 Neoplasm
 (P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT P-glycoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT Drug resistance
 (antitumor; P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT Drug delivery systems
 (capsules; P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT Resolution (separation)
 (chromatog.; P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT Biological transport
 (drug; P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT Antitumor agents
 (resistance to; P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT 52-53-9, Verapamil 56-54-2, Quinidine 57-83-0, Progesterone, biological studies 865-21-4, Vinblastine 9000-83-3, ATPase 10540-29-1, Tamoxifen 20830-81-3, Daunorubicin 21829-25-4, Nifedipine 33069-62-4, Paclitaxel 62669-70-9, Rhodamine 123 65277-42-1, Ketoconazole
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT 193275-84-2, SCH 66336
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT 403487-60-5P
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)


IT 403494-42-8P
 RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation) (P-glycoprotein inhibitors for treating multidrug resistance in refractory tumor cells)

IT 124-63-0, Methanesulfonyl chloride 693-98-1, 2-Methylimidazole 40465-45-0, p-Cyanophenyl isocyanate 403493-27-6
 RL: RCT (Reactant); RACT (Reactant or reagent) (P-glycoprotein inhibitors for treating multidrug resistance in

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 403494-42-8 REGISTRY
CN 1-Piperazinecarboxylic acid, 4-[8-chloro-6-[(2-methyl-1H-imidazol-1-yl)methyl]-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-, 1,1-dimethylethyl ester, (-)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H32 Cl N5 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

refractory tumor cells)
IT 403487-55-8P 403487-56-9P 403487-57-0P 403487-58-1P 403487-59-2P
471282-65-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(P-glycoprotein inhibitors for treating multidrug resistance in
refractory tumor cells)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	9.00	75.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'REGISTRY' ENTERED AT 11:51:10 ON 18 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 APR 2005 HIGHEST RN 848640-07-3
DICTIONARY FILE UPDATES: 17 APR 2005 HIGHEST RN 848640-07-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> S 403494-42-8/RN

L5 1 403494-42-8/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L5 SQIDE 1-